Development
Sarepta's siRNA conjugate SRP-1005 enters Phase I for Huntington's disease
Sarepta Therapeutics has registered a first-in-human Phase I trial of SRP-1005 (formerly ARO-HTT), an siRNA conjugate designed to silence the huntingtin...
Abogen's mRNA in vivo bispecific T-cell engager shows early promise in B-cell lymphoma
Abogen presented preliminary Phase I ABO2203 clinical results at the AACR Annual Meeting 2026 in San Diego from a first-in-human dose-escalation study of...
Nektar's rezpegaldesleukin shows Phase II promise as JAK alternative in hair growth
Nektar Therapeutics (Nasdaq: NKTR) reported that rezpegaldesleukin, its investigational IL-2 pathway agonist, continued to generate new hair growth...
Roche aiming to add SLE indication for Gazyva after positive Phase III
Roche (SIX: RO; OTCQX: RHHBY) announced that the FDA has accepted its supplemental Biologics License Application for obinutuzumab (Gazyva/Gazyvaro) in...
Immunocore's tebentafusp doubles five-year survival in metastatic uveal melanoma Phase III trial
Immunocore Holdings (Nasdaq: IMCR) reported five-year overall survival data from the Phase III CT029 trial at AACR 2026, showing that tebentafusp (Kimmtrak)...
Sanofi's Nuvaxovid shows significantly better tolerability than Moderna's mNEXSPIKE in Phase IV COVID-19 trial
Sanofi (Nasdaq: SNY) reported that its recombinant protein-based COVID-19 vaccine Nuvaxovid produced statistically significant lower systemic reactogenicity...
Agenus emphasizes positives after Phase II miss in PD-1 refractory gastroesophageal cancer
Agenus Inc. (Nasdaq: AGEN) reported Phase II data from an investigator-initiated trial combining botensilimab, balstilimab, and agenT-797 in PD-1 refractory...
Asahi Kasei puts peptide TNF receptor 1 anatagonist into first-in-human study
Asahi Kasei Therapeutics Corp. has initiated a Phase I clinical trial for AK1940, a peptide-based selective antagonist of tumor necrosis factor receptor 1...
Lantern Pharma's LP-300 shows 8.3-month median progression-free survival in EGFR L858R lung cancer
Lantern Pharma (Nasdaq: LTRN) reported a median progression-free survival of 8.3 months for LP-300 in 16 patients with EGFR Exon 21 L858R-mutant non-small...
AstraZeneca's tozorakimab meets primary endpoint in Phase III MIRANDA COPD trial
AstraZeneca (LSE/STO/NYSE: AZN) reported that tozorakimab met its primary endpoint in the Phase III MIRANDA trial, reducing the annualised rate of...
Novo Nordisk's etavopivat meets dual endpoints in Phase III sickle cell disease trial
Novo Nordisk reported that etavopivat met both co-primary endpoints in the Phase III HIBISCUS trial, reducing vaso-occlusive crisis events by 27% and...
GlycoNex puts ADC targeting aberrant glycosylation into first-in-human for GI cancers
GlycoNex, Inc. (4168), a Taiwan-based clinical-stage biotechnology company, announced on April 14 that Japan's Pharmaceuticals and Medical Devices Agency...
Marengo's invikafusp alfa shows complete responses in metastatic breast cancer trial
Marengo Therapeutics reported initial Phase 2a results from the STARt-002 trial of invikafusp alfa combined with sacituzumab govitecan (TRODELVY) in heavily...
Kestrel's pan-KRAS inhibitor swoops into Phase I for advanced solid tumors
Kestrel Therapeutics, a Watertown, Massachusetts-based biotechnology company, has opened a first-in-human Phase I clinical trial for KST-6051, an oral...
METiS TechBio's enters MTS109 into Phase I for refractory autoimmune disease
Shanghai Changzheng Hospital has opened enrollment in the first-in-human MTS109 clinical trial (NCT07526350), testing an mRNA-encoded, lipid...
The AllSci Brief
Systematic R&D and deal news. Daily.